Tim Smith

Dupilumab showed strong results for uncontrolled moderate-to-severe hand and foot atopic dermatitis, meeting its primary and secondary endpoints in the trial.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.

In this interview segment, Damsky spoke more about his conference presentation on JAK inhibitors, describing his response to safety concerns and other information.

Damsky discussed his conference presentation on the application of JAK inhibitors on dermatologic conditions such as granuloma annulare and sarcoidosis.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

New phase 3 trial data was announced by Dermavant Sciences indicating strong results for both efficacy and safety of tapinarof treatment for atopic dermatitis.

New research was conducted into treating Stevens-Johnson syndrome/toxic epidermal necrolysis patients with plasmapheresis before intravenous immunoglobulin therapy.

A new study indicated that body surface area predicted erythema-type chronic graft-vs-host disease survival more accurately than NIH Skin Scores.

Recent data highlighted the relationship between different blood types and acne severity, identifying correlations between specific groups.

A new post-hoc analysis used 5 clinical trials on dupilumab to assess the drug’s effectiveness with and without topical corticosteroids for atopic dermatitis/eczema patients.

New research assessed the association between perceived stress and cognitive function in Black and White adults, finding that stress screening for high-risk adults may be needed.

Data presented in a research letter suggests that medicinal-thermal waters found in a spring in Las Salinas (near Madrid) had positive effects on plaque psoriasis.

New data demonstrated that the combined use of prednisone and methotrexate saw positive results in hair regrowth for patients with alopecia totalis or alopecia universalis.

In a research letter, patient perspectives were explored regarding access to dermatology clinic notes, with more than half reporting improved understanding due to notes.

In another interview segment, Castells discussed the safety profile of avapritinib for indolent systemic mastocytosis, as well as future research.

Research indicates that a potential reduction in healthcare costs could result from utilization of biosimilars for adalimumab and etanercept in dermatology.

In another interview segment, Castells went further into depth regarding the PIONEER trial results and regarding avapritinib’s effect on mastocytosis.

New data from AAAAI was described by Castells, who explained some of the background of the recent PIONEER trial on avapritinib for mastocytosis patients.

Novan announced on Tuesday that the FDA accepted the New Drug Application (NDA) for Berdazimer Gel, a topical antiviral molluscum contagiosum treatment, for review.

In a recent letter to the editor, a newly-developed tool to assess one’s satisfaction with life when dealing with food allergy was introduced.

A recent study reviewed several educational interventions designed to promote food allergy literacy and knowledge for both parents and children.

New data from a study on adult vitiligo patients indicates that both autoimmune/autoinflammatory and non-autoimmune comorbidities have higher occurrence rates for vitiligo patients.

New findings have indicated that alopecia areata, alopecia totalis, and alopecia universalis, may disproportionately affect Asian Americans and other people of color.

In recent data presented at the AAAAI annual meeting, dupilumab was found to have outperformed both mepolizumab and omalizumab in FEV1 improvement for asthma patients.

Data shown at the AAAAI annual meeting showed that chronic spontaneous urticaria activity and DLQI rankings were higher following dupilumab treatment.

Data presented at the AAAAI annual conference showed that delayed cutaneous reactions were more reported following Moderna COVID-19 vaccination than other vaccines.

New data presented at the AAAAI annual meeting showed that a significant number of patients recommended to be evaluated for drug allergy never completed their diagnostic tests.

Data presented at the AAAAI annual meeting showed that machine learning models had a high accuracy rate in penicillin allergy prediction, though researchers concluded that more data is needed before adoption.